Synribo approved to treat rare leukemia

October 26, 2012

(HealthDay)—Synribo (omacetaxine mepesuccinate) has been approved by the U.S. Food and Drug Administration to treat a rare blood and bone marrow disease called chronic myelogenous leukemia (CML).

Some 5,430 people will be diagnosed with CML this year, the U.S. National Institutes of Health estimates. Synribo has been sanctioned to treat cases in which two other specific anti-cancer drugs have failed to stop CML's progression, the FDA said Friday in a news release.

Synribo is designed to be injected twice daily in different regimens for a number of consecutive days until white blood cell counts normalize, the agency said.

The most common adverse reactions observed during clinical testing included anemia, a drop in infection-fighting , nausea, weakness, fatigue and injection-site reaction.

Synribo is marketed by the Israeli drug maker Teva Pharmaceuticals, with U.S. headquarters in Frazer, Pa.

Explore further: Omontys approved for anemic people with kidney disease

More information: The U.S. National Library of Medicine has more about CML.

Related Stories

Kyprolis approved for multiple myeloma

July 20, 2012

(HealthDay) -- Kyprolis (carfilzomib) has been approved by the U.S. Food and Drug Administration to treat certain people with multiple myeloma who have already been given at least two prior therapies.

Marqibo approved for ph- acute lymphoblastic leukemia

August 10, 2012

(HealthDay) -- Marqibo (vincristine sulfate liposome injection) has been approved by the U.S. Food and Drug Administration to treat adults with Philadelphia chromosome negative acute lymphoblastic leukemia (ALL).

Marqibo approved for rare leukemia

August 10, 2012

(HealthDay) -- Marqibo (vincristine sulfate liposome injection) has been approved by the U.S. Food and Drug Administration to treat adults with a rare form of blood and bone marrow cancer, Philadelphia chromosome negative ...

New drug approved for lack of certain white blood cells

August 30, 2012

(HealthDay)—The U.S. Food and Drug Administration has approved the drug tbo-filgrastim to treat certain cancer patients undergoing chemotherapy who have a condition called severe neutropenia, the FDA said in a news release.

Recommended for you

Scientists block breast cancer cells from hiding in bones

May 25, 2016

Scientists at the Duke Cancer Institute have identified a molecular key that breast cancer cells use to invade bone marrow in mice, where they may be protected from chemotherapy or hormonal therapies that could otherwise ...

Genetic sequencing reveals drug resistance growth

May 25, 2016

The rate at which genetically mutated cancer cells grow may help explain why patients with a common form of leukemia develop treatment resistance, according to new research led by a Weill Cornell Medicine investigator. The ...

Taking control of key protein stifles cancer spread in mice

May 20, 2016

For cancer to spread, the cells that take off into the bloodstream must find a tissue that will permit them to thrive. They don't just go looking, though. Instead, they actively prepare the tissue, in one case by co-opting ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.